Original Research Article
3-Year Study of Donepezil Therapy in Alzheimer’s Disease: Effects of Early and Continuous TherapyWinblad B.a · Wimo A.b · Engedal K.c · Soininen H.d · Verhey F.e · Waldemar G.f · Wetterholm A.-L.g · Haglund A.g · Zhang R.h · Schindler R.h
aKarolinska University Hospital Huddinge, Stockholm, and bNeurotec, Karolinska Institutet, Stockholm, Sweden; cDepartment of Geriatric Medicine, Ullevaal University Hospital, Oslo, Norway; dDepartment of Neurology, University and University Hospital of Kuopio, Kuopio, Finland; eDepartment of Psychiatry, Institute of Brain and Behaviour, Maastricht Hospital University, Maastricht, The Netherlands; fThe Neuroscience Center, Department of Neurology, Rigshospitalet, University Hospital, Copenhagen, Denmark; gPfizer, Täby, Sweden; hPfizer Global Pharmaceuticals, Pfizer, New York, N.Y., USA
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Delays in the diagnosis of Alzheimer’s disease, and, therefore, delays in treatment, may have a detrimental effect on a patient’s long-term well-being. This studyassessed the effects of postponing donepezil treatment for 1 year by comparing patients treated continuously for 3 years with those who received placebo for 1 year followed by open-label donepezil for 2 years. Patients (n = 286) with possible or probable Alzheimer’s disease (according to DSM-IV, NINCDS-ADRDA, and Mini-Mental State Examination criteria; see text) were randomized to receive donepezil (5 mg/day for 4 weeks, 10 mg/day thereafter) or placebo (delayed-start group) for 1 year. Of the 192 completers, 157 began a 2-year, open-label phase of donepezil treatment. Outcome measures were the Gottfries-Bråne-Steen scale, the Mini-Mental State Examination, the Global Deterioration Scale, the Progressive Deterioration Scale, the Neuropsychiatric Inventory, and safety (adverse events). Mixed regression analysis was used to compare changes between the groups over 3 years on the efficacy measures. There was a trend for patients receiving continuous therapy to have less global deterioration (Gottfries-Bråne-Steen scale) than those who had delayed treatment (p = 0.056). Small but statistically significant differences between the groups were observed for the secondary measures of cognitive function (Mini-Mental State Examination; p = 0.004) and cognitive and functional abilities (Global Deterioration Scale; p = 0.0231) in favor of continuous donepezil therapy. Over 90% of the patients in both cohorts experienced one treatment-emergent adverse event; most were considered mild or moderate. In conclusion, patients in whom the start of treatment is delayed may demonstrate slightly reduced benefits as compared with those seen in patients starting donepezil therapy early in the course of Alzheimer’s disease. These data support the long-term efficacy and safety of donepezil.
© 2006 S. Karger AG, Basel
- Rogers SL, Doody RS, Mohs RC, Friedhoff LT: Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998;158:1021–1031.
- Rogers SL, Farlow MR, Doody RS, Mohs RC, Friedhoff LT: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Donepezil Study Group. Neurology 1998;50:136–145.
- Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Moller HJ, Rogers SL, Friedhoff LT: The effects of donepezil in Alzheimer’s disease – results from a multinational trial. Dement Geriatr Cogn Disord 1999;10:237–244.
- Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, Wetterholm AL, Zhang R, Haglund A, Subbiah P: A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001;57:489–495.
- Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, Pratt RD; ‘312’ Study Group: A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001;57:481–488.
- Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, Edwards S, Hardyman W, Raftery J, Crome P, Lendon C, Shaw H, Bentham P; AD2000 Collaborative Group: Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet 2004;363:2105–2115.
- Doody RS, Geldmacher DS, Gordon B, Perdomo CA, Pratt RD: Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001;58:427–433.
- Raskind MA, Peskind ER, Wessel T, Yuan W: Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000;54:2261–2268.
- Farlow M, Anand R, Messina J Jr, Hartman R, Veach J: A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer’s disease. Eur Neurol 2000;44:236–241.
- Petkova E, Teresi J: Some statistical issues in the analyses of data from longitudinal studies of elderly chronic care populations. Psychosom Med 2002;64:531–547.
Teresi J: Overview of methodological issues in the study of chronic care populations. Alzheimer Dis Assoc Disord 1994;8(suppl 1):S247–S273.
- Thomas RG, Berg JD, Sano M, Thal L: Analysis of longitudinal data in an Alzheimer’s disease clinical trial. Stat Med 2000;19:1433–1440.
- La Rue A: Methodological concerns: longitudinal studies of dementia. Alzheimer Dis Assoc Disord 1987;1:180–192.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 1994.
- McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–944.
- Folstein MF, Folstein SE, McHugh PR: ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
- Gottfries CG, Bråne G, Gullberg B, Steen G: A new rating scale for dementia syndromes. Arch Gerontol Geriatr 1982;1:311–330.
- Bråne G, Gottfries CG, Winblad B: The Gottfries-Bråne-Steen scale: validity, reliability and application in anti-dementia drug trials. Dement Geriatr Cogn Disord 2001;12:1–14.
Bråne G, Gottfries CG: The GBS scale in an international perspective. Brain Aging Int J 2002;2.
- Reisberg B, Ferris SH, de Leon MJ, Crook T: The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982;139:1136–1139.
- Eisdorfer C, Cohen D, Paveza GJ, Ashford JW, Luchins DJ, Gorelick PB, Hirschman RS, Freels SA, Levy PS, Semla TP, et al: An empirical evaluation of the Global Deterioration Scale for staging Alzheimer’s disease. Am J Psychiatry 1992;149:190–194.
- DeJong R, Osterlund OW, Roy GW: Measurement of quality-of-life changes in patients with Alzheimer’s disease. Clin Ther 1989;11:545–554.
- Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308–2314.
Littell RC, Milliken GA, Stroup WW, Wolfinger RD: SAS System for Mixed Models. Cary, SAS Institute, 1996.
Raskind MA, Peskind ER, Truyen L, Kershaw P, Damaraju CV: The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. ArchNeurol 2004;61:252–256.
- Rogers SL, Doody RS, Pratt RD, Ieni JR: Long-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol 2000;10:195–203.
- Smith F: Mixed-model analysis of incomplete longitudinal data from a high-dose trial of tacrine (Cognex) in Alzheimer’s patients. J Biopharm Stat 1996;6:59–67.
- Finkel SI, Mintzer JE, Dysken M, Krishnan KR, Burt T, McRae T: A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer’s disease in outpatients treated with donepezil. Int J Geriatr Psychiatry 2004;19:9–18.
- Mendiondo MS, Ashford JW, Kryscio RJ, Schmitt FA: Modelling Mini-Mental State Examination changes in Alzheimer’s disease. Stat Med 2000;19:1607–1616.
- Salmon DP, Thal LJ, Butters N, Heindel WC: Longitudinal evaluation of dementia of the Alzheimer type: a comparison of 3 standardized mental status examinations. Neurology 1990;40:1225–1230.
- Mortimer JA, Ebbitt B, Jun SP, Finch MD: Predictors of cognitive and functional progression in patients with probable Alzheimer’s disease. Neurology 1992;42:1689–1696.
- Brooks JO III, Yesavage JA, Taylor J, Friedman L, Tanke ED, Luby V, Tinklenberg J: Cognitive decline in Alzheimer’s disease: elaborating on the nature of the longitudinal factor structure of the Mini-Mental State Examination. Int Psychogeriatr 1993;5:135–146.
- Rockwood K, Black SE, Robillard A, Lussier I: Potential treatment effects of donepezil not detected in Alzheimer’s disease clinical trials: a physician survey. Int J Geriatr Psychiatry 2004;19:954–960.
- Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR: Donepezil is associated with delayed nursing home placement in patients with Alzheimer’s disease. J Am Geriatr Soc 2003;51:937–944.
- Burns A, Jacoby R, Levy R: Psychiatric phenomena in Alzheimer’s disease. IV. Disorders of behaviour. Br J Psychiatry 1990;157:86–94.
- Petry S, Cummings JL, Hill MA, Shapira J: Personality alterations in dementia of the Alzheimer type: a three-year follow-up study. J Geriatr Psychiatry Neurol 1989;2:203–207.
- Gauthier S, Feldman H, Hecker J, Vellas B, Ames D, Subbiah P, Whalen E, Emir B: Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer’s disease. Int Psychogeriatr 2002;14:389–404.
- Feldman HH, van Baelen B, Kavanagh SM, Torfs KE: Cognition, function, and caregiving time patterns in patients with mild-to-moderate Alzheimer disease: a 12-month analysis. Alzheimer Dis Assoc Disord 2005;19:29–36.
- Devanand DP, Jacobs DM, Tang MX, Castillo-Castaneda C, Sano M, Marder K, Bell K, Bylsma FW, Brandt J, Albert M, Stern Y: The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry 1997;54:257–263.
- Levy ML, Cummings JL, Fairbanks LA, Bravi D, Calvani M, Carta A: Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer’s disease. Am J Psychiatry 1996;153:1438–1443.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.